OPGx-LCA5
Gene therapy / editing
Evidence outlook · registrational
Leber Congenital Amaurosis: registrational readout pending
No completed mid-stage readout is on record. No upcoming registrational readout date is posted to the registry. Check News for topline announcements. The sponsor reported topline results of a Phase 1/2 study on 2025-09-30 (Positive pediatric and adult data from OPGx-LCA5 Phase 1/2 trial); that is not the registrational readout.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT05616793 NCT05616793 · LCA5 Registry: NCT05616793 | 1/2 | Incidence of Dose Limiting Toxicities (2 years); Number of adverse events related to OPGx-001 (2 years); Incidence of adverse events related to OPGx-001 (2 years); Severity of adverse events related to OPGx-001 (2 years); Number of procedure-related adverse events (2 years); Incidence of procedure-related adverse events (2 years); Severity of procedure-related adverse events (2 years); Assessment of cross-sectional spectral domain optical coherence tomography images (2 years); Assessment of Natural course of LCA5-IRD (6 months); Assessment of Natural course of LCA5-IRD (6 months); Assessment of Natural course of LCA5-IRD (6 months); Assessment of Natural course of LCA5-IRD (6 months); Assessment of Natural course of LCA5-IRD (6 months); Assessment of Natural course of LCA5-IRD (6 months); Assessment of Natural course of LCA5-IRD (6 months) 2028-06-15 | In progress: results expected 15 Jun 2028 | not yet graded | link ↗ |
View 1 more trial
— · Leber Congenital Amaurosis No ClinicalTrials.gov record: the sponsor states "the last patient has been enrolled in its registrational phase 3 clinical trial evaluating OPGx-LCA5" | 3 | — | — | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 1/2 (1)
What this study did
Competitive landscape
No competitors sharing a mechanism or indication in the current universe.
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow OPGx-LCA5 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2028 (1)
June 2028 (1)
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent